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INTRODUCTION 
INTRODUCTION 
 
 Eclampsia is a form of Hypertensive encephalopathy with generalised 
convulsions associated with signs of preeclampsia during pregnancy, labour 
(or) within 7 days of delivery and not caused by epilepsy (or) other 
convulsive disorders. It is one of the important causes of mortality and 
morbidity during pregnancy, child birth & puerperium. 
 
 Of the estimated 7,00,000 maternal deaths every year world wide 10% 
to 15% are associated with Hypertensive disorder of pregnancy. 
 
 The incidence of Eclampsia in developing countries is 0.5 – 2% but 
4.9%/10,000 in United Kingdom1 and 1 in 2000 in Europe and developed 
countries. 
 
 Eclampsia accounts for 50,000 maternal deaths a year world wide. 
 
 The maternal case fatality rate is 1.8% and 35% of eclamptics will 
have one major complication. 
 
 Perinatal mortality rate in developed countries is less than 10/1000 
births to as high as 80 (or) more/1000 births in developing countries. The 
Collaborative Eclampsia Trial group found that the incidence of perinatal 
mortality in eclampsia ranges from 224 to 307/1000 cases of Eclampsia.2 
According to Mudhaliar, perinatal mortality in Eclampsia is 300 – 600/1000 
cases of Eclampsia. The overall PNMR Eclampsia is 363/1000 cases of 
Eclampsia. 
 
 Although it is a standard practice to use anti convulsants for 
management of Eclampsia, the choice of agent is controversial. Until recently, 
the pharmacological treatment of eclampsia has been determined by 
geography, habit and tradition. Magnesium sulphate is the drug of choice in 
US, in Britain and in many parts of world. 
 
 Collaborative Eclampsia Trial shows – Not only does magnesium 
sulphate diminish the risk of further convulsions, but it also produces less 
maternal and neonatal morbidity than the other agents.3 
 
 A smaller study carried out at Dhaka Medical College at the same time 
as the CET came to exactly the same conclusions. The main difference 
between these 2 studies was the dosage regimen of magnesium sulphate. 
 
 The loading does of Dhaka was significantly less than that used by 
Collaborative Eclampsia Trial - 10g loading does compared with 14gm. The 
lower dosage had been chosen because of small size of Bangladesh woman. 
The evidence was considered by a working party of Eclampsia in October 
1997. It was agreed that the Regime validated for local use would be 
recommended for National use.4 Guidelines were prepared and disseminated. 
With this regimen the mortality rates in Dhaka medical college have fallen 
dramatically.5 
 
 This study compares the Pritchard Regimen with Dhaka regimen of 
magnesium sulphate in management of Antepartum eclampsia. 
 
  
 
 
 
 
AIM OF THE STUDY 
AIM OF THE STUDY 
 
1) To study the effect of low dose Magnesium sulphate Regimen - Dhaka 
Regimen in Antepartum Eclampsia. 
 
2) To compare the effects of Magnesium sulphate regimens – Dhaka 
regimen with Pritchard regimen. 
i) The efficacy of controlling convulsions 
ii) In preventing recurrent convulsions. 
iii) The incidence of complications.  
  
 
 
 
 
REVIEW OF LITERATURE 
REVIEW OF LITERATURE 
 
Definition:- 
 Preeclampsia complicated by generalised tonic-clonic convulsions is 
termed eclampsia. Fatal coma without convulsions also called as eclampsia, 
however it is better to limit the diagnosis to woman with convulsions and to 
regard deaths in non convulsive cases as due to severe preeclampsia. 
 
 Depending on whether convulsions appear before, during (or) after 
labour, eclampsia is designated as Antepartum, Intrapartum (or) Post partum. 
 
Etiology: 
 Etiology of Pregnancy induced Hypertension. 
 
1) Abnormal trophoblastic Invasion:  
 In pre eclampsia, there is incomplete trophoblastic invasion of uterine 
spiral arteries6. Endothelial damage, insudation of plasma constituents into 
vessel wall, proliferation of myointimal cells & medial necrosis are observed.7 
 
 Lipid laden myointimal cells and macrophages – atherosis8 causes 
obstruction of spiral arterioles. 
 
2) Immunological Factors:- 
 The risk of preeclampsia is enhanced where formation of Blocking 
Antibodies to placental antigenic sites might be impaired. They arise where 
effective immunisation by previous pregnancy is lacking as in first pregnancy 
(or) in multiple pregnancy where number of Antigenic sites provided by the 
placenta is great compared to the amount of antibody – Beer (1978) 9  
 
 Bardeguez and associates (1991)10 – woman who develop 
preeclampsia have lower proportion of helper T cells (Th1) than normotensive 
woman. Th1/Th2 imbalance with Th2 dominance may be mediated by 
adenosine, which is higher in serum of preeclampsia woman than 
normotensives. 
 
 Preeclampsia common in woman with anticardiolipin antibodies, 
Antibodies associated with β2 glycoprotein 1 appear more relevant. Immune 
complexes and anti endothelial cell antibodies may also be involved (Taylor 
and Roberts, 1999)11 
 
3) Genetic Factors: 
 Ness (2003)12 suggested that the tendency for preeclampsia is 
inherited. Cooper and Liston (1979) suggested that susceptibility to pregnancy 
induced Hypertension is due to single recessive gene13 Chesley and Cooper 
(1986) suggested single gene model14. Trogstad and coworkers (2004) 
suggested polygenic inheritance.15 Kilpatrick and associates (1989) showed 
association between HLA-DR4 and proteinuric Hypertension.16 
 
 Ward and Zhang (2003) reported that woman heterozygous for 
angiotensinogen gene variant T235 had a higher incidence of preeclampsia of 
fetal growth restriction17. Morgan and colleagues (1995, 1999) did not 
confirm this, but they found that woman homozygous for the mutation had 
abnormal trophoblastic invasion.18 
 
 Polymorphisms of genes for TNF, Lymphotoxin –α and interleukin – 
1β have been studied with varying results19 (Hefler; Lachmeijer; Livingstor 
2001). 
 
 Dizon Townsend and colleagues (1996) found higher incidence of 
factor V    leiden mutations in pregnancy induced hypertensive woman. 20 
 
4) Nutritional Factors:- 
 A number of dietary deficiencies (or) excess have been blamed as a 
cause of eclampsia. Dietary taboos included are meat, protein, purines, fat, 
dairy products salt and others. 
 
 John and coworkers (2002) showed that a diet rich in fruits and 
vegetables have antioxidant activity with decreased blood pressure. 
 
 Zhang and associates showed that the incidence of preeclampsia was 
doubled in woman whose daily intake of ascorbic acid was less than 85mg.21 
 
 Carroli and colleagues (1994) implicated that calcium supplementation 
reduces the risk of preeclampsia.22 
 
 Belizan (1991), Lopez-Jeramillo (1989), Sanchez-Ramos (1994)23 and 
their associates reported that mid pregnancy daily dietary supplementation of 
2gm calcium significantly reduced the incidence of Hypertension. 
 
5) Vasculopathy and the inflammatory Changes:- 
 In response to placental factors released by ischemic changes, (or) any 
other inciting cause, a cascade of events is set in motion (Redman and Sargent 
2003)24 
 
 Staff and colleagues 1999 – suggested that the decidua also contains an 
abundance of cells when activated, can release noxious agents.25 They serve 
as mediators to provoke endothelial cell injury. 
 
 Fass and colleagues 2000 and Gervasi 2001, showed that preeclampsia 
is due to an extreme state of activated leucocytes in maternal circulation.26 
 
 TNF –α and their interleukins may contribute to the Oxidative stress 
associated with preeclampsia. 
 
 Oxidative stress produce highly toxic radicals and injure endothelial 
cells (Manten and associates 2005)27 modify their nitric oxide production and 
interfere with prostaglandin balance. 
 
PATHOGENESIS 
1) Vasospasm: 
 The concept of vasospasm was advanced by Volhard (1918)28 based on 
direct observation of small vessels in nail beds, ocular fundi and bulbar 
conjunctiva. Wang and colleagues (2002) demonstrated disruption of 
endothelial junctional proteins.29 Suzuki and co workers (2003) demonstrated 
ultrastructural changes in sub endothelial region of resistance arteries in 
preeclamptic woman.30 Vasospasm may be worse in HELLP syndrome – 
Fischer and colleagues, 2000.31 
 
2) Endothelial cell activation:- 
 Hayman, Roberts, Walker 2000 showed that clinical syndrome of 
preeclampsia result from widespread endothelial cell changes.32 
(i) Increased Pressor responses:- 
 Abdul – Karim and Assali 1966 showed that normal pregnant woman 
develop refractoriness to infused Vasopressors.33 
 Woman with early preeclampsia, have increased vascular reactivity to 
infused nor epinephrine and angiotensin II.34 (Raab and co workers 1956. 
Talledo and associates, 1968) 
 
ii) Prostaglandins:- 
 Taylor and Roberts (1999) showed that endothelial prostacyclin 
production is decreased in preeclampsia that is mediated by phospholipase 
A2.35 
 
 Platelet produced thromboxane A2 increased and the prostacyclin : 
thromboxane A2 ratio decreases. That favours increased sensitivity to 
angiotensin II that ends in Vaso constriction. 
 
 Chavarria (2003) given the evidence that these changes are apparent as 
early as 22weeks in woman who later develop preeclampsia. 
 
iii) Nitric Oxide: 
 A potent vasodilator synthesized from L-arginine by endothelial cells. 
It is the compound that maintains normal low pressure vasodilator state 
characteristic of Feto placental perfusion – Myatt and co workers 1992.36 
 Wang and colleagues showed that preeclampsia is associated with 
decreased endothelial nitric oxide synthase expression, which increases cell 
permeability. It’s production increased as compensatory mechanism in severe 
preeclampsia37. So increased serum concentration of nitric oxide is likely the 
result of hypertension, not the cause – Morris and colleagues 1996. 38 
 
iv) Endothelins: 
 Mastrogiannis and coworkers showed that these 21 amino acid 
peptides are potent vaso constrictors, and endothelin -1 (ET-I) is primary 
isoform produced by human endothelium.39 
 
 Taylor and Roberts (1999) showed that the placenta is not the source of 
increased ET-I.40 
 
 Sagsoz and Kucukozkan 2003 observed that treatment of preeclamptic 
woman with magnesium sulphate lowers ET-I concentrations.41 
 
v) Angiogenic Factors: 
 Vascular endothelial growth factor (VEGF) and placental growth 
factor (PIGF), the glycosylated Glycoproteins are selectively mitogenic to 
endothelial cells. 
 
 Simmons and co workers 2000 showed the VEGP is increased in 
serum from woman with preeclampsia but the bioavailability is decreased42. 
 
 In preeclampsia, the gene for Soluble Fms-Like tynosine kinase 1 
(SFLt) is upregulated – Maynard & associates.43 
 
Pathophysiology 
 
Maternal vascular  Faulty Placentation  Excessive trophoblast 
Disease 
 
Genetic, Immunologic 
Inflammatory factor 
 
 
Reduced uteroplacental 
Perfusion 
 
Vasoactive agents      Noxious agents 
Prostaglandins       Cytokines 
Nitric Oxide       Lipid peroxide 
Endothelins    Endothelial 
     Activation 
 
Vasospasm   Capillary leak           Activation of coagulation 
 
 
Hypertension Oliguria    Liver Edema   Proteinuria     Thrombocytopenia 
           ischemia 
                 Seizures          abruption Hemoconcentration 
 
Clinical Course of eclampsia 
 Eclampsia is most common in last trimester and becomes more 
frequent as term approaches. 
 
 Maternal hypoxia and lactic acidosis caused by convulsions, the fetus 
develops bradycardia, pulmonary edema may occur. Sudden death due to 
massive cerebral hemorrhage can occur. 10% of cases had blindness due to 
retinal detachment (or) occipital lobe ischemia and edema. Rarely eclampsia 
is followed by psychosis. 
 
Differential diagnosis:- 
 Epilepsy, encephalitis, meningitis cerebral tumor, cysticercosis and 
ruptured cerebral aneurysm. 
 
Complications of Eclampsia:  
Placental abruptions (10%), Neurological deficits (7%) Aspiration 
pneumonia (7%) pulmonary edema (5%) cardiopulmonary arrest (4%) Acute 
renal failure (4%) maternal death (1%). 
 
 
 
 
MANAGEMENT 
 
I. General Management 
 It plays an important role in the management of eclampsia. The patient 
is nursed in a quiet room with a medical or nursing attendant always present. 
Pulse rate, respiration, blood pressure, colour, restlessness, urine output must 
be constantly observed. A mouth gag, airway and O2 must be available. 
Patient is put in left lateral position in a railed cot. Throat is cleared of 
secretions and vomitus by intermittent suction. A soft firm mouth gag 
introduced in time will save injury to the tongue. An indwelling catheter in 
the bladder will give an accurate assessment of the urine output and will also 
prevent restlessness due to a full bladder (Dewhurst 1984). Blood pressure is 
measured half hourly till it is controlled and then second hourly. A record of 
grade of consciousness is maintained. Nutrition and hydration are maintained 
parenterally. 
 
II. Anticonvulsant line of Management 
History 
 In the early years of the 20th century early intervention to achieve 
delivery was widely practiced. The mortality was very high. Later in 1930, 
Strongonoff introduced his conservative regimen of heavy sedation with 
morphia by injection, and chloral or bromide per rectum gave better results. 
Once the convulsions were fully controlled the membrane were ruptured. 
 In 1920-30 stomach and colonic lavage with magnesium sulphate was 
used to clear the patient of toxins and sedation with chloroform. 
 
 In 1951-1960 barbiturates were used. ‘O’ Donnel Browned used 
continuous thiopentone in 20% dextrose, but causes marked cerebral 
depression. 
 
 In 1961, lytic cocktail regimen using pethidine, chlorpromazine and 
promethazine was introduced by Dr. M.K.K. Menon 44. He treated 1448 cases. 
Recurrence of fits was 15%. Maternal mortality was 2.4%. 
 
 Nager et al (1988) treated 98 cases with lytic cocktail (LC) with 
maternal mortality rate of 8.2%. 
 
 Llewellyn Jones (1961) conducted a study on 150 cases of eclampsia 
with lytilcocktail and the maternal mortality was 6.6% 45. 
 
 Lopez Liera used lyticocktail on 120 eclmaptic women and the 
maternal mortality was 11.7%.46 
 
 Lean et al (1968) have reported excellent results with large doses of 
chlordiazepoxide or diazepam. 
 Magnesium sulphate was first used by Horn in Germany in 1906 intra 
thecally 47. In 1926 intravenous regimen of magnesium sulphate was reported 
by Lazard in Los Angeles and intramuscular regimen by Dorsett in St. Louis. 
However the popular intra muscular regimen of Pritchard was introduced in 
1955 and intravenous regimen by Zuspan in 1964. 
 
 Phenytoin Sodium was introduced in management of eclampsia in 
1987. 
 
DOSAGE SCHEDULE OF VARIOUS REGIMENS 
 
1.  Menon’s Regimen (1961) 
0 Hours 
25 mg chlorpromazine and 100 mg pethidine in 20 ml of 5% 
glucose given intravenously. 50 mg chlorpromazine and 25 mg 
promethazine given intramuscularly. 
 
A drip of 20% dextrose containing 200 mg pethidine is set up 
and run slowly at a rate of 20-30 drops / minute. 
 
 
 
 
0-4 hrs Promethazine 25 mg Im 
0-8 hrs Chlorpromazine 50 mg Im 
0-12 hrs Promethazine 25 mg Im 
0-16 hrs Chlorpromazine 50 mg Im 
0-20 hrs Promethazine 25 mg Im 
0-24 hrs Chlorpromazine 50 mg Im 
0-28 hrs Promethazine 25 mg Im 
0-32 hrs Chlorpromazine 50 mg Im 
0-36 hrs Promethazine 25 mg Im 
0-40 hrs Chlorpromazine 50 mg Im 
0-44 hrs Promethazine 25 mg Im 
0-48 hrs Chlorpromazine 50 mg Im 
 
Menon (1961) used lyticocktail in 1448 eclamptic women and 
maternal mortality was 2.2%.48 
 
Llewllyn Jones (1961) in his study using lyticcocktail had a 
maternal mortality of 6.6%.49 Lopez Liera (1982) in his study had 
a maternal mortality of 11.7%.50 Bhalla et al (1994) in his study using 
lyticcocktail had a maternal mortality of 4.4%.51 
 
 
2.  Diazepam (1968) 
A loading dose of 10 mg diazepam intravenously over 2 
minutes followed by an intravenous infusion of 40 mg in 500 ml 
normal saline for 24 hours. Rate of infusion titrated against level of 
consciousness with the aim of keeping the woman sedated but 
arousable. Diazepam can cause respiratory depression. It is poorly 
excreted by the neonate which tends to be sedated, hypothermic and 
unable to breast feed for several days. 
 
3.  Chlordiazepoxide (1968) 
An initial intravenous injection of 10 mg followed by a 
continuous injection of 100 mg in 500 ml of 5% dextrose at a rate of 30 
drops / minute or titrated according to the sedation needed. 
 
4.  Clonazepam (1977) 
1 mg intra venous bolus followed by an intravenous infusion of 
2.5 mg in 500 ml of 5% dextrose. 
 
5.  Chlormethiazole (Duffs et al 1968) 
It is an effective anticonvulsant. Intra venous infusion of 0.8% 
chlormethiazole in 500 ml of 5% dextrose at a rate of 2-4 gm / hour for 
first 5-10 minutes and 0.5-1 gm / hour thereafter to produce easily 
arousable sleep. It has a short half life of 45 minutes, so does not 
produce prolonged sedation in the mother or neonate. 
 
6.  Magnesium Sulphate (MgSo4) 
In 1955 Pritchard initiated a standardized treatment regimen at 
Parkland Hospital. 
  
 In 1964 Zuspan initiated the intravenous magnesium sulphate 
regimen. 
 
a) Pritchard Regimen 
Loading Dose Maintenance Dose 
4 g of 20% MgSo4 IV at a rate not 
exceeding 1 g / min 
Every 4 hrs 5 gm of 50% MgSo4 as IM on 
alternate buttocks after assuring 
10 g of 50% MgSo4 deep IM in 
buttocks 
a) Patellar reflex is present 
b) Respiration are not depressed > 16 / 
minute 
c) Urine output > 100 ml in preceeding 
4 hours 
If convulsions persists after 15 
minutes, give 2 g of 20% MgSo4 at a 
rate not exceeding 1 gm / minute 
MgSo4 discontinued 24 hours after delivery 
b) Zuspan’s Regimen (1964) 
 
Loading Dose Maintenance Dose 
4 g of 20% MgSo4 IV at a rate not 
exceeding 1 g / min 
1-2 g / hour by controlled infusion 
pump for 24 hours after delivery 
(concentration not to exceed 20%) 
 
c) University of Tennessee guidelines for intravenous mgso4 
 
Loading Dose 
Give 30ml of 20%mgso4 solution (6g) in 100ml of 5% dextrose over 
10 to 15minutes. 
 
Maintenance Dose: 
 Add 20g of mgso4 (Four 10ml ampoules of 50% solution to 1000ml of 
5% Dextrose and give intravenously at a rate of 100ml/hour (2g/hour). Adjust 
the rate of infusion to keep serum magnesium levels between 4.8 & 9.6mg/dl. 
 
 If serum magnesium levels are not available the dose is adjusted 
according to the patellar reflex and urine output in previous 4hour period. 
 
Monitoring of Magnesium Toxicity: 
 Urine output atleast 30ml / hour. 
 Deep tendon reflexes should be present. 
 Respiratory rate should exceed 14/min. 
 
d) Dhaka Regimen:- 
 This prospective study was undertaken at Dhaka Medical College 
Hospital between 25 March and 15 June 1998. 
 
 It has the approval of the Hospital research Ethics committee. The 
agreed guidelines for management of eclampsia patients were followed.52The 
regime used was that from the Dhaka study.53 
 
 4gm magnesium sulphate given intravenously slowly over 15 minutes 
along with 3gm given intramuscularly in each buttock as a loading dose-
maintenance therapy was 2.5gm every 4 hours, given intramuscularly in 
alternate buttocks until 24 hours after administration of the first dose. 
 
 Patients were monitored every 30 minutes for the first 6hours, then 
hourly by observing respiratory rate, knee jerk, urine out put. 
 
Phenytoin Regimen :- 
 Slater et al – Woman weight 40-50 kg  = 750 mg 
   51-70 kg    = 1000 mg 
   > 70 kg   = 1250 mg 
 
 First 250mg is diluted in 250m I of normal saline and infused a rate of 
25mg/minute Rest given over 15minutes. After 12hours 500mg of phenytoin 
given as intravenous infusion (or) orally. 
 
ECTG(1995)54 
¾ 1 gm by slow intravenous infusion over 20mts is the loading dose  
¾ 100mg every 6th hourly for next 24hours 
 
Dommisse(1990)54 
¾ 0.5-1 gm intravenously over 20minutes 
¾ 0.5gm over next 1 hour then 
¾ 0.5gm over 4hours, 12hours over staring treatment.  
 
Lucas et al(1995)55 
¾ 1 gm intravenously over 1 hour is the loading dose 
¾ 500mg orally 10hour later 
¾ continued for 24hours post partum 
 
Appleton54 
¾ 10mg/Kg as intravenous infusion at a rate of 25-40mg/minute is the 
loading dose. 
¾ 5mg/kg as intravenous infusion 5hours later. 
¾ 200mg every 8hours initiated .12hours after second dose until 24hours 
post delivery. 
Coyagi et al (1994) 56 
Used single dose of 900mg phenytoin sodium as intravenous infusion. 
Control of convulsions was adequate without need for any complicated drug 
related patient monitoring. 
 
PHARMACOKINETICS 
 
Magnesium Sulphate 
 It has a molecular weight of 246. 1 gm of magnesium sulphate has 
98mg of elemental magnesium. 
 
Distribution and plasma levels57,58 
Infused magnesium sulphate is distributed rapidly throughout the entire 
extra cellular fluid space and some is taken up by bone but none by red blood 
cells. Intravenous loading dose of 4-6gm results in immediate plasma 
concentration of 5-9mg/dl and it falls to 3-4gm/dl in 60minutes. Within 
90minutes 50% of infused magnesium moves into bones and other cells. By 
4hours 50% of infused Magnesium is excreted in the urine.  
 
Excretion 
Magnesium is excreted almost solely by the Kidneys. 50% of the 
infused dose is excreted after 4 hours in urine. 99% of the bolus intravenous 
dose is excreted within 24hours. 
 
Mechanism of action 
Some believe its action to be mainly peripheral at the neuro muscular 
junction with minimal central effects. While some believe that the main action 
is central. Calcium entry into neurons is regulated by specific excitatory 
amino acid linked channels. Excitatory amino acids such as L-glutamate and 
L-aspartate are the major neuro transmitters in mammalian central nervous 
system. These neurotransmitters produce their effects by interacting with 
certain receptors on the cell surface, the excitatory amino acid receptors, N-
methyl D-aspartate (NMDA) is the best characterised excitatory amino acid 
receptor sub type. NMDA receptor has its channel blocked by magnesium ion 
and thus blocking neuronal calcium influx. Thus magnesium has a central 
nervous system effect in blocking the seizure. Cotton and associates (1992) 
have shown that hippocampal seizures could be blocked by magnesium 59 
 
Magnesium sulphate is a potent vasodilator especially in cerebral 
vasculature thus relieving cerebral vasospasm which is thought to be a cause 
for eclampsia. 
Other Actions 
¾ Vaso dilatation in Vascular beds 
¾ Increased uterine blood flow (Harbert &collegues) 
¾ Increased renal blood flow 
¾ Increased prostocyclin release by endothelial cells (Watson and 
Colleagues) 
¾ Decreased plasma renin activity 
¾ Decreased angiotensin converting enzyme levels 
¾ Attentuation of vascular response to pressor substances 
¾ Bronchodilatation 
¾ Reduced platelet aggregation 
 
Pharamacological effects 
¾ Anti convulsant action 
¾ Transient hypotensive effect 
¾ Transient but mild decrease in frequency of uterine contractions but no 
change in the intensity of contractions. 
¾ Clinically insignificant decrease in short term variability of fetal heart 
rate. 
¾ No change in long term variability of fetal heart rate or fetal heart rate 
accelerations 
 
Side Effects 
First sign of magnesium toxicity is usually the loss of patellar reflexes 
that occurs usually at about 9-12mg/dl because of curariform action. So 
maintenance does of MgS04 is not to be given in the absence of patellar 
reflexes. 
 
Early signs and symptoms of magnesium toxicity include nausea, 
feeling of warmth, flushing, somnolence, double vision, slurred speech and 
weakness. These symptoms usually develop at plasma levels of 9 to12mg/dl. 
 
Muscle paralysis and respiratory arrest develop at plasma level of 15-
17mg/dl. Hence respiratory rate is monitored closely. 
 
Cardiac arrest develops at level a of 30-35mg/dl. Thus it is important to 
keep an ampoule containing 1 gram of calcium gluconate at the bedside for 
intravenous administration as an antidote in case of magnesium toxicity. 
 
Tracheal intubation and mechanical ventilation for severe respiratory 
depression (or) arrest. There is a transient decrease in uterine activity during 
intravenous injection alone. It can cause a transient decrease in fetal heart rate 
variability, neonatal neuro muscular and respiratory depression hyporeflexia 
and low apgar scores. These effects were reported in preterm infants in 
association with fetal growth retardation. In addition several recent studies 
reported no ill effects in term infants. It can cause excessive blood loss after 
delivery. 
 
Efficacy and Safety 
Rapidly effective, reliable & predictable duration of action, wide  
safety margin, non depressive and non toxic to the mother and baby, simple to 
administer and monitor in the clinical setting and readily available antidote. 
Serum magnesium can be measured to ensure therapeutic concentration but 
many practitioners are happy to omit biochemical monitoring because of its 
wide margin of safety.60 
 
Duley et al (1995) in his study used clinical evaluation alone and 
showed that the there is no need to check serum magnesium levels Estimation 
of magnesium levels are useful in the management of treatment failures. 
 
Drug interactions with Magnesium Sulphate 
Agent Effect Recommendation 
Depolarising / non 
depolarizing neuro 
muscular blockers 
Increased activity of 
these agents 
May need dosage reduction 
of neuro muscular blocking 
agents 
 
Agent Effect Recommendation 
CNS depressants eg 
opioids, barbiturates, 
general anaesthetics 
Additive CNS 
depression 
May require dose reduction 
of CNS depressants 
Nifedipine Hypotension Administer with caution and 
adjust nifedipine dosage if 
necessary 
 
 At the neuromuscular junction magnesium decreases the presynaptic 
release of acetylcholine and reduces the sensitivity of the post junctional 
membrane (motor end plate). Ghoneim and long reported that the action of 
succinylcholine (non depolarizing agent) are potentiated by magnesium 
sulphate. A single dose of succinylcholine can be safely used to facilitate 
tracheal intubation but may not apply when repeated dose of succinyl choline 
are used.61 
 
 When a patient is simultaneously exposed to magnesium sulphate and 
nifedipine some interaction might be expected as both are calcium channel 
blockers. Fenakel et al (1998) studied nifedipine in women who are receiving 
magnesium sulphate and found effective blood pressure control in 96% 
women without hypertension. It would appear that while a theoretical risk of 
interaction could exist in practice this is relatively uncommon.61 
Alpha Methyl dopa 
This was introduced to treat hypertension in 1960 by sjoerdesma 
 
OH
OH CH2 COOHC
CH2
NH2
 
Pharmacological action 
After oral (or) intravenous administration the hypotensive effect 
appears after 3 to 6 hours and 1-2 hours respectively. Hypotensive effect is 
associated with reduced cardiac output and total peripheral resistance. It does 
not reduce renal blood flow. 
 
Mechanism of action 
1. Inhibits adrenergic receptors in the vasomotor center 
2. Inhibits renin release by the kidneys 
 
Absorption and Excretion 
It is well absorbed orally and completely excreted in urine in 12 hours. 
 
CH3 
Adverse Effects 
It commonly produces sedation, headache and fatigue. Other side 
effects are diminished Intellectual drive, drowsiness, forgetfullness, night 
'mares parkinsonism, lactation and depression. Tolerance to antihypertensive 
effect is common. It can cause drug fever, altered liver function test (or) 
cholestatic jaundice. Rarely agranulocytosis, thrombocytopenia, 
gastrointestinal tract upset, constipation and skin rashes. 
  
Nifedipine 
It a calcium channel blocker, introduced in clinical practice in 1970 by 
Flerk, and Entus in 1971. 
NH
CH2
COCH2
NO2
COCH2
 
 
PHARMACOLOGICAL ACTIONS 
It blocks the calcium transport through voltage dependent channel and 
thus inhibits the entry of extra cellular calcium ion necessary for the 
excitation contraction coupling in both the skeletal muscle and smooth 
muscle. It has a negative inotropic action on heart, relaxes the vascular 
smooth muscle in systemic as well as pulmonary circulation. Thus decreases 
the vascular resistance and the blood pressure. If causes a reflex tachycardia. 
It can be used orally or sublingually. 
 
Side effects 
It produces headache, tachycardia, dizziness, fatigue, orthostatic 
hypotension, leg cramps and skinrashes. 
 
Interactions 
Some have advised caution while using nifedipine with magnesium 
sulphate as both are calcium channel blockers, which may have a depressive 
effect on blood pressure. 
 
Fenakel et al (1998) studied nifedipine in women who were receiving 
magnesium sulphate and found effective blood pressure control in 96% 
women without undesirable side effects and no cases of hypotension. It would 
therefore appear that while a theoretical risk of interaction does exist. In 
practice this is uncommon.  
 
Bhalla et al (1994) in his study used nifedipine and magnesium 
sulphate and had a good control of blood pressure.  
 
Other Antihypertensives 
Intravenous hydrallizine (or) intravenous labetalol produces 
remarkably effective control of the high blood pressure. 
  
OBSTETRIC MANAGEMENT 
After stabilizing the patient a detailed obstetric examination was made. 
If she is in labour, amniotomy was done and oxytocin infusion was started. If 
she is not in labour induction with prostaglandin E2 gel done for a favourable 
cervical score. 
 
Cesarean section was for obstetric indication, for failure of medical 
treatment. 
 
I Stage 
During labour fetal heart rate was ausculated every fifteen minutes, 
blood pressure was recorded every 2nd hourly. Intake, output was maintained 
strictly. Maternal pulse was recorded hourly. Cardiovascular system and 
respiratory system were ausculated every 2nd hourly. Intravenous fluids 
preferably ringer lactate was infused at a rate of 1 ml/kg / hour. 
 
II Stage 
Completed by forceps, if indicated. 
 
III Stage 
Prophylactic methyl ergometrine was usually avoided to prevent the 
rise in blood pressure. 
  
Blood Pressure was recorded every 2nd hourly until controlled and 
then' every 4th hourly for 48hours. All other vital signs and urine output were 
recorded every second hourly for 48 hours after delivery. 
 
 
  
 
 
 
 
MATERIALS & METHODS 
MATERIALS & METHODS 
 
 This study was conducted in Government Rajaji Hospital, Madurai 
during the period of July 2005 – July 2006. 
 
 60 consecutive patients with antepartum eclampsia were included in 
the study. Magnesium sulphate was used in control of convulsions. 30 
patients were put under the Prichard regimen and other 30 were enrolled 
under Dhaka regimen. 
  
History: 
 A detailed history regarding age, parity, gestational age, number of 
convulsions, duration of symptoms of pregnancy induced Hypertension, H/o 
imminent symptoms were taken from close relations and also from the patient 
if she is conscious (or) taken retrospectively from her. Any past history of 
hypertension (or) renal disease (or) Eclampsia in previous pregnancy was 
elicited. 
 
Clinical Examination: 
 A through general examination and obstetric examination was made. 
 On general examination, conscious level, degree of edema, anaemia, 
blood pressure pulse rate, temperature, respiratory rate, cardiovascular 
system, Respiratory system, fundus examination were done, Blood and urine 
were sent for all investigations related to eclampsia like Renal functions test, 
Liver functions, haematological investigations were carried out in all patients.  
 
 A life line was established and the Regimen was started. Hourly urine 
output was measured by an indwelling catheter. Half hourly pulse, 
temperature and respiratory rate, two hourly blood pressure were taken. 
Serum magnesium levels measured. 
 
ANTI CONVULSANT LINE OF MANAGEMENT 
 
1) DHAKA REGIMEN OF MAGNESIUM SULPHATE REGIMEN: 
Loading Dose: 
 4gm of magnesium sulphate given intravenously slowly over 
15minutes. 
 3gm given intramuscularly in each buttock. 
 
Maintenance Dose: 
 2.5gm every 4 hours given intramuscularly in alternate buttocks, until 
24hrs after administration of the first dose. 
 Monitored with urine output kneejerks, and respiratory rate. 
 
2) PRITCHARD REGIMEN OF MAGNESIUM SULPHATE REGIMEN 
4gm of Magnesium sulphate (Mgso4, 7H2o, USP) as a 20% solution 
intravenously at a rate not to exceed 1gm/min. Follow promptly with 10gm of 
50% Magnesium sulphate solutions 5gm deep IM in each buttock. 
 
 5gm of 50% solution of magnesium sulphate every 4hours thereafter 
for 24 hours after delivery provided, 
a) Patellar reflex is Present. 
b) Respiratory Rate > 16/min 
c) Urine output the previous 4hr exceeded 100ml. 
 
Anti Hypertensive Line of Management: 
 Control of Hypertension achieved by T. Alphamethyl Dopa 250mg 
thrice daily and T. Nifidipine 10mg twice daily. 
 
Obstetric Management: 
 After stabilizing the patient, a detailed obstetric examination was done. 
Mode of termination was planned according to the gestational age, viability of 
the fetus, and the cervical scoring. 
 
 Patients were induced with prostaglandin E2 gel and accelerated with 
Oxytocin infusion. 
 Cesarean section was done for obstetric indications (or) for failed 
inductions. 
 
 After delivery the patient was observed carefully for 48 – 72 hours in 
the labour ward and post operative ward and followed up till the discharge of 
the patient. 
 
 Neonatal outcome was recorded in terms of Apgar scoring and birth 
weight. Neonates also followed up till the discharge of the mother. 
 
Outcome Measures: 
 Primary outcome measures are recurrence of fits after starting the 
treatment in both the regimens. Perinatal mortality and maternal morbidity 
were compared in both groups. 
 
  
 
 
 
 
RESULTS AND ANALYSIS 
RESULTS AND ANALYSIS 
 
 The study was done to compare the effectiveness of 2 regimens of 
magnesium sulphate Pritchard & Dhaka regimens. All woman with 
antepartum eclampsia were eligible and follow up was until discharge from 
hospital. 
 
A. CHARACTERISTICS OF THE CASES STUDIED 
Table : 1 Age 
 
Age Group Group A (Dhaka Regimen) Group B (Pritchard 
Regimen) 
No % No % 
< 20 2 6.7 4 13.3 
20 – 24 18 60 18 60 
25 – 29 8 26.7 6 20 
30 & above 2 6.7 2 6.7 
Total 30 100 30 100 
Mean 23.1 22.8 
S.D 3.6 3.6 
P 0.7711 
 
Age of Women in the two groups does not differ significantly. 
 
In this study 6 cases (10%) were below 20years, 36 cases (60%) were 
between 20-24yrs, 14 cases (23%) were 25-29years and 4 cases (7%) were 30 
years and above. 
 
 The mean age for Pritchard regimen is 22.8years and Dhaka regimen 
was 23.1yrs and the P value is 0.7711 which is insignificant.  
  
Table : 2 Booking Status 
 
Booking 
Status 
Group A (Dhaka Regimen) Group B (Pritchard 
Regimen)  
No % No % 
Booked 10 33.3 11 36.7 
Un booked 20 66.7 19 63.3 
P 0.7883 (Not Significant) 
 
In Pritchard regimen the booked cases were 36.7% in Dhaka regimen 
the booked cases were 33.3%. 
 
 The unbooked cases of Pritchard regimen was 63.3% and Dhaka 
Regimen was 66.7% 
 
 The p value of 0.7883 was insignificant.  
Table : 3 Parity 
 
Parity Group A (Dhaka Regimen) Group B (Pritchard 
Regimen) 
No % No % 
Primi 20 66.7 12 40 
Multi 10 33.3 18 60 
P 0.07 
 
 Parity in the two groups does not differ significantly. 
 
 In our study 32 cases were primis. In Dhaka regimen 66.7% were 
primis. In CET trial group (1995) – 64% were primis. According to mudhaliar 
over 75% were primis. The p value being 0.07, the parity in two groups does 
not differ significantly. 
 
Table : 4 Gestational Age 
 
Gestational 
Age 
Group A (Dhaka Regimen) Group B (Pritchard 
Regimen) 
No % No % 
< 24 weeks 4 13.3 4 13.3 
25 – 28 3 10 5 16.7 
29 – 32 9 30 9 30 
33 – 36 9 30 7 23.3 
> 36 5 16.7 5 16.7 
Mean 31.87 31.13 
S.D 4.63 4.89 
P 0.56 
 
 In our study 8 cases (13.3%) were below 24weeks size (13.35%) 8 
cases were 25-28 weeks. 18 cases (30%) were 29-32 weeks, 16 cases (26.6%) 
were between 33-36weeks. 10 cases (16.7%) were > 36 weeks size. 
 
 The mean gestational age of Pritchard regimen was 31.13 weeks. The 
mean gestational age for Dhaka Regimen was 31.87 weeks. The p value is 
0.56, which is insignificant. 
 
 In a study by Katz and colleagues 2000 the mean gestational age 
during seizures was 34.2 weeks. 
 
Table : 5 Level of Consciousness 
 
Level of 
Consciousness 
 
Group A (Dhaka Regimen)  Group B  (Pritchard 
Regimen) 
No % No % 
Conscious 9 30 11 36.7 
Semi conscious 21 70 19 63.3 
P 0.7842 
 
 Level of consciousness of the mothers in the two groups does not differ 
significantly. 
 
 The conscious patients on Pritchard Regimen 11 cases (36.7%) Dhaka 
Regimen 9 cases (30%). The semiconscious patients in Pritchard Regimen 19 
cases (63.3%) Dhaka Regimen 21 cases (70%). 
 
 The p value being 0.7842 the level of consciousness of the mothers in 
both groups does not differ significantly. 
 
 
 
 
Table : 6 Number of fits before admission 
 
No of fits 
before 
admission 
Group A (Dhaka 
Regimen) 
Group B (Pritchard 
Regimen) 
P 
No. % No. % 
1-2 14 46.7 20 66.7 
0.5165 
3-5 13 43.3 9 30 
6-8 2 6.7 1 3.3 
>9 1 3.3 0 0 
Mean 
S.D. 
2.93 
2.46 
2.4 
1.35 
 
 Total number of fits before admission ranged between 1-9 fits giving a 
mean value of 2.93 at Dhaka regimen group and 2.4 in Pritchard Regimen 
Group. 
 
 The p value being 0.5165 the number of fits in both regimens carries 
insignificant role. 
 
Table 7 : Recurrence of convulsions after starting the Regimen 
 
Convulsions after 
starting the regimen 
Group A (Dhaka 
regimen) 
Group B (Pritchard 
regimen) 
No. % No. % 
Nil - - - - 
1 3 10 4 13.3 
>1 - - - - 
P 0.5 (Not significant) 
 
 In Group A 10% had one convulsion and Group B 13.3% had one 
convulsion and they needed a repeat dose of magnesium sulphate and the fits 
were controlled – none had more than one convulsion. 
 
 
 
 
Table : 8 Hypertension 
 
B.P 
 
Group A (Dhaka Regimen) Group B  (Pritchard 
Regimen) 
No. % No. % 
SBP 
120-140 
140-160 
>160 
 
3 
15 
12 
 
10 
50 
40 
 
3 
17 
10 
 
10 
56 
34 
DBP 
80-90 
100-110 
>110 
 
3 
22 
5 
 
10 
73 
17 
 
2 
18 
10 
 
6.7 
60 
33.3 
P 0.7407 (Not Significant) 
 
 Majority of the cases have systolic blood pressure of 140-160 mm Hg - 
Dhaka Regimen group (50%) and in Pritchard Regimen group 56%. 
 
 Majority of the cases have diastolic blood pressure of 100-110 mm Hg 
- Dhaka Regimen group (73%) and in Pritchard Regimen group 60%. 
 
 
 The p value being 0.7407 the diastolic BP doesn’t make much 
difference in both regimens. 
 
Table : 9 Serum magnesium mg/dl 
 
Serum Magnesium Group A (Dhaka 
Regimen) 
Group B (Prichard 
Regimen) 
Mean 4.69 5.01 
S.D 0.3 0.4 
P 0.0023 
 
 The mean serum magnesium level of Pritchard regimen was 5.01mg/dl 
 
 The Dhaka regimen was 4.69mg/dl 
 
 Both were within the therapeutic levels without going for toxicity. 
 
Table 10 : Mode of Induction 
 
Mode of 
induction 
Group A  (Dhaka Regimen) Group B  (Pritchard 
Regimen) 
No % No % 
Syntocinon 7 23.2 5 16.7 
Gel 23 76.7 25 83.3 
P 0.7469 
 
 In 30 cases of Pritchard Regimen 5 cases induced with 
Syntocinon and 25 cases with Prostaglandin E2 gel. 
 
 In 30 cases of Dhaka Regimen 7 cases were induced with 
Syntocinon and 23 cases with Prostaglandin E2 gel. 
 
  The p value being 0.7469 which is insignificant. 
 
B. OUTCOME IN THE TWO GROUPS 
 
Table : 11 Mode of delivery 
 
Mode of delivery 
 
Group A (Dhaka 
Regimen)   
Group B (Pritchard 
Regimen) 
No % No % 
Vaginal 
LN delivery 
Outlet forceps 
Assisted Breech Delivery 
27 
23 
3 
1 
90 
76.7 
10 
3.3 
28 
24 
3 
1 
93.3 
80 
10 
3.3 
C.S 3 10 2 6.7 
P 0.5 (Not Significant) 
 
 Out of 30 cases of Pritchard regimen 24 cases delivered by labour 
natural 3 cases by forceps 1 case as assisted breech delivery and 2 cases by 
LSCS. 
 
 Out of 30 cases of Dhaka Regimen 23 cases delivered by labour 
natural 1 cases as assisted breech delivery of  3 cases by forceps and 3 cases 
by LSCS. 
 Out of 5 cases delivered by LSCS. 
 2 cases were due to failed induction. 
 2cases were due to fetal distress. 
 1 case due to impending renal failure. 
Table : 12 Admission to delivery interval 
 
Admission to 
delivery 
interval 
 
Group A  
(Dhaka Regimen)  
Group B  
(Pritchard Regimen) 
No.  % No.  % 
< 6 hours 5 17.9 7 23.3 
6.1 – 12 hours 15 53.6 11 36.7 
12.1 – 18 hours 6 21.4 10 33.3 
> 18 hours 2 7.1 2 6.7 
Mean 10.97 hours 11.81 hours 
S.D 4.1 5.37 
P 0.5926 
 
 The mean duration of Admission – Delivery interval for Pritchard 
Regimen was 11.81hours and for Dhaka Regimen was 10.97 hours. In both 
Regimens only 2 cases in each delivered after 18 hours. 
 
 
 
 
 
Table : 13 Condition of mother after delivery 
 
Condition of 
mother 
 
Group A  
(Dhaka Regimen)  
Group B  
(Pritchard Regimen)    
No. % No. % 
Alive 30 100 30 100 
Dead - - - - 
 
 In both Regimens there is no maternal mortality and they followed up 
in labour ward for 48-72 hours. 
 
Table : 14 Condition of child after delivery 
 
Condition of 
Child 
 
Group A  
(Dhaka Regimen)  
Group B  
(Pritchard Regimen) 
No. % No. % 
Alive 18 62.1 19 63.3 
Still born 4 13.8 5 16.7 
Neonatal 
death 
7 24.1 6 20.0 
P 0.7923 (Not Significant) 
 
Perinatal Outcome:- 
 Born alive in Pritchard regimen was 19 cases (63.3 %) Dhaka 
Regimen 18 cases (62.1%). 
 Still born in Pritchard Regimen was 5 cases (16.7%) 
In Dhaka Regimen 4 cases (13.8%) 
 The neonatal death with Pritchard regimen 6 cases (20%). In 
Dhaka Regimen 7 cases (24.1%) 
 
The p value being 0.7923 the condition of the child doesn’t differ 
significantly in both the regimens. 
 
Table 15 : Birth weight of babies in the two groups 
 
Birth weight 
(in kg) 
Group A  
(Dhaka Regimen)  
Group B  
(Pritchard Regimen) 
No. % No. % 
< 1 3 10 3 10 
1-1.5 7 23.3 7 23.3 
1.6-2.5 15 50 14 46.7 
>2.5 5 16.7 6 20 
Mean 1.84 1.81 
S.D. 0.61 0.58 
P 0.801 (Not significant) 
 
 There is no significant difference in the birth weight of the children in 
the two groups. 
 
Perinatal mortality in relation to the birth weight of babies 
 
Birth weight 
(in kg) 
Cases Perinatal 
Mortality 
% 
< 1 6 5 83.3 
1-1.5 14 8 57.1 
1.6-2.5 29 7 24.1 
>2.5 11 2 18.2 
  
As birth weight increases, perinatal mortality decreases. 
Table 16 : Perinatal mortality Rate 
 
 Total Cases Perinatal deaths 
No. % 
Group A 30 11 36.7 
Group B 30 11 36.7 
 
The perinatal mortality rate does not differ in both the regimens. 
 
Maternal Morbidity 
Dhaka Regimen No. % 
Wound infection 
Urinary tract infection 
Puerperal psychosis 
Puerperal sepsis 
1 
2 
1 
2 
3.35 
6.65 
3.35 
6.65 
 
 
Pritchard Regimen No. % 
Hemiplegia improved with Physiotherapy 
Urinary tract infection 
Puerperal sepsis 
Wound infection 
1 
2 
1 
2 
3.35 
6.65 
3.35 
6.65 
 
 
  
 
 
 
 
DISCUSSION 
DISCUSSION 
 
 Prevention of further fits in eclampsia is associated with a reduction in 
adverse outcomes.62 Magnesium is an ideal drug, with rapid onset of action, a 
non sedative effect on mother and baby, a fairly wide safety margin and a 
readily available antidote in the form of calcium gluconate.63 The 
Collaborative Trial provided vital evidence that magnesium reduces the risk 
of recurrent seizures compared to other standard agents diazepam and 
phenytoin. Further more use of magnesium sulphate does not appear to be 
associated with detrimental effects on the neonate.64 
 
 Evidence from computed tomography and magnetic resonance 
angiographic studies implicating cerebral vasospasm and ischemia in the 
genesis of eclampsia.65 Magnesium seems to reverse and ameliorate the 
effects of cerebral ischemia.66 
 
 There may also be a moderate inhibitory effects on cortical discharge. 
67 With magnesium antagonizing the excitatory glutamate N-methyl aspartate 
receptor.68 
 
 Falling serum calcium levels following administration of Intra venous 
magnesium sulphate inhibit acetyl choline release at motor end plate. It 
depends upon serum calcium level.69 
 
 In our study we used total of 10gm mgso4 as a loading does and 2.5gm 
4 hourly which is just over half the dose used by Pritchard and an 
Collaborative Eclampsia Trial. 
 
Age Distribution 
 A study in N.W.M. Hospital, Bombay in 1989 reveals that 40.5% were 
under 20 years, 56.8% were between 21-29 and 2.7% above 30 years. 
Lolkand et al in his study (1997) found that 40.7% were under 20 years. In a 
study by Katz VL and colleagues (2000) in the sacred heart medical center 
USA the mean age of eclampsia was 22 years. 
  
 In our study the mean age in Dhaka regimen is 23.1 years and mean 
age in Pritchard regimen is 22.8 years.  
 
Parity 
 In the study of eclmapsia collaborative trial Group (1995) 64% were 
primis. In the study by N.W.M. Hospital, Bombay 1989 64.9% were primis. 
According to Mudaliar over 75% were primis. In a study by Lalkoand et al 
(1997) 57.3% were primis. In our study in Dhaka regimen 66.7% were primis 
and in Pritchard regimen 40% were primis. 
 
Gestational Age 
 In ECTG study 39.5% cases were less than 34 weeks and 25.5% cases 
were presented between 34-36 weeks and 33% cases were presented at term. 
In our study mean gestational age in Dhaka regimen was 31.87 weeks and in 
Pritchard regimen 31.13 weeks. 
 
Diastolic Blood Pressure 
 In ECTG study 53% had a diastolic blood pressure above or equal to 
110 mm Hg. In our study majority of cases were Diastolic blood pressure 
between 100-110 mm Hg and in Dhaka regimen 73% and in Pritchard 
regimen 60%. 
 
Recurrence rate of convulsions 
 The recurrence rate of convulsions after starting the regimen in 
Dommisse (1990) – 0%, ECTG (1995) – 5.7%, PGI Chandigarh – 8.1%. In 
our study 10% in dhaka regimen and 13.3% in Pritchard regimen. 
 
Mode of induction  
 Alexander and colleagues (1999) reviewed 278 singleton liveborn 
infants weighing 750-1500 gms delivered of woman with severe pre 
eclampsia in Parkland hospital. 50% were induced and 50% underwent 
caesarean delivery without labor. Induction was not successful in 35% of 
women of induced group. Similar results were reported by Nassar and 
colleagues (1918). 
 
 In our study in Dhaka regimen 23.2 cases induced with syntocinon and 
76.7% induced with prostaglandin E2 gel. Among them 90% successfully 
delivered vaginally. 10% underwent caesarean section. 
 
 In Pritchard regimen 16.7% induced with syntocinon and 83.3% with 
prostaglandin E2 gel.Among them 93.3% delivered vaginally and 6.7% by 
caesarean section due to failed induction and medical causes. 
 
Perinatal Mortality 
 Perinatal deaths in Eclampsia Trial Collaborative Group (1995) with 
Magnesium sulphate was 25% with Diazepam 22% with Phenytoin 31%. In 
our study both Dhaka and Pritchard Regimens the perinatal death was 36.7%. 
 
Maternal Mortality 
 The maternal mortality between 1991-1997 approximately 6% in US 
were related to eclampsia. (Berg & coworkers 2003). The maternal mortality 
with ECTG study 1995 5.2%, Eclampsia Trial Collaborative Group 1995 with 
magnesium sulphate was 3.8%. In our study both the Dhaka regimen and 
Pritchard regimen no maternal death occurred. 
 
 No patient developed toxicity with low dose Dhaka Regimen. The 
earliest sign of toxicity would be loss of tendon reflexes which usually occur 
when serum levels of 10mg/dl are reached. 
 
 The range of serum magnesium concentration in Dhaka Regimen was 
4.69mg%. This lies within Pritchard’s therapeutic range. 
 
 In our study 76% patients regained consciousness within 6-12 hours.  
 
 Recent evidence has suggested that in-utero exposure to magnesium 
may be associated with higher 1 minute Apgar score and a lower prevalence 
of cerebral palsy. 
 
  
 
 
 
SUMMARY 
SUMMARY 
                                                
No. of Cases Dhaka Regimen  
30 
Pritchard Regimen 
30 
Recurrence of fits 
No. of cases  
(%) 
 
3 
10% 
 
4 
13.3 % 
Serum Magnesium Level 
Mean Level 
 
4.69 mg % 
 
5.01 mg % 
Mode of Delivery 
Vaginal  
LSCS 
 
27 (90%) 
3 (10%) 
 
28 (93.3%) 
2 (6.7%) 
Perinatal Outcome 
Live Born 
Still Born 
Neonatal death 
PNMR 
 
18 (62.1%) 
4 (13.8%) 
7 (24.1%) 
36.7% 
 
19 (63.3 %) 
5 (16.7%) 
6 (20%) 
36.7% 
Maternal Morbidity 7 (23.3%) 6 (20%) 
 
 In this study, 30 eclamptic cases were treated with Pritchard regimen and 
compared with another 30 cases which were treated with Dhaka regimen. 
 Recurrence of fits after starting the regimen was lower in both the 
magnesium sulphate regimen groups. 
 Only 4 cases (13.3%) in the Pritchard group had recurrence of fits, 
whereas, 3 cases (10%) in the Dhaka group had recurrence of fits. 
 80 % cases in both groups delivered within 18 hours of admission. 
 93.3% (28 cases) in the Pritchard group and 90 % (27 cases) in the Dhaka 
group delivered vaginally. 
 The mean serum magnesium level of Pritchard regimen is 5.01 mg% and 
Dhaka regimen is 4.69 mg%. 
 2 cases (6.7%) in the Pritchard group and 3 cases (10%) in the Dhaka 
group are delivered by LSCS. 
 19 babies (63.3%) in the Pritchard group and 18 babies (62.1%) in the 
Dhaka group were born alive. 
 5 babies (16.7%) in the Pritchard group and 4 babies (13.8%) in the Dhaka 
group were still born. 
 Maternal morbidity was 20% in Pritchard regimen and 23.3 % in Dhaka 
regimen. 
 The perinatal mortality rate doesn’t differ in both the groups. 
  
 
 
 
 
CONCLUSION 
CONCLUSION 
 
 Magnesium sulphate is the anti convulsants drug of choice in woman 
with eclampsia. 
 
 The low dose Dhaka Regimen used for smaller woman appears to 
control and prevent convulsions effectively. 
 
 Our study of Dhaka Regimen showed that serum levels remain below 
the toxic levels. 
 
 The present study provides further strong support for the routine use of 
magnesium sulphate for eclampsia convulsions. 
 
 As long as there is adequate urinary output clinical monitoring appears 
to be sufficient. 
 
 There is no difference in maternal mortality, perinatal mortality, 
maternal morbidity and cesarean section rates among the both magnesium 
sulphate regimens. 
 
 Like the Pritchard regimen the admission to delivery interval was 
lower in Dhaka regimen. 
 
 The study clearly shows that Dhaka regimen is almost equivalent to 
Pritchard regimen, on control of convulsions on eclampsia cases. 
 
 Proper antenatal care, improved socio economic status and intensive 
management will largely reduce the incidence of eclampsia which is an 
important cause of maternal morbidity and perinatal mortality. 
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S.No. Name Group Age yrs 
Booked 
Unbook
ed 
parity Obst. Code 
GA
wks
Level
of 
cons.
At 
adm.
No. of 
fits 
before 
adm. 
HT BP SYS DIA 
Sr. 
Mg.
mg/
dl 
MOI MOD
Admn. 
Deliver 
interval
hrs 
Condition 
after del 
mother 
B. 
Weight
kg 
Baby
No.of 
fits 
after 
deli. 
1 Mariammal A 25 2 MULTI G2P1L1 32 2 10 2 150 100 4.4 1 1 6 1 1.7 1 0 
2 Mariammal A 23 1 MULTI G2A1 30 2 2 1 140 100 4.2 2 1 9 1 0.9 2 0 
3 Sundarammal A 33 1 MULTI G3P2L2 34 2 2 2 150 100 4.6 2 1 7 1 1.75 1 0 
4 Kavitha A 25 1 MULTI G2P1L1 24 1 3 2 150 110 4.2 1 1 13 1 1.1 3 1 
5 Ponselvi A 20 2 Primi Primi 36 1 3 1 140 100 4.8 2 1 8 1 2 1 0 
6 Mekala A 25 1 Primi Primi 36 2 3 2 200 120 5 1 1 10 1 2.1 1 0 
7 Pullani A 25 1 Primi Primi 24 2 3 2 170 110 4.8 2 2 19 1 1.25 2 0 
8 Noorjahan A 21 1 Primi Primi 34 1 1 2 150 120 4.6 2 2 16 1 2.7 3 0 
9 Ponnalagu A 20 2 MULTI G2P1L1 24 2 3 2 200 120 4.2 1 1 6 1 0.9 2 0 
10 Mareeswari A 20 2 Primi Primi 28 1 1 2 190 110 5 2 1 9 1 1.3 3 1
11 Selvi A 24 2 Primi Primi 34 2 1 2 220 140 4.8 1 1 3 1 2.3 1 0 
12 Indira A 19 2 MULTI G2A1 28 2 3 2 160 100 4.6 2 1 12 1 1.5 1 0 
13 Pitchaiammal A 20 2 Primi Primi 38 2 2 2 180 120 4.4 1 1 4 1 32 1 0 
14 Rojabans A 22 2 Primi Primi 30 2 4 2 150 100 4.8 2 1 12 1 1.2 2 0 
15 Selvi A 26 2 Primi Primi 38 1 3 2 150 100 5.2 2 1 19 1 2 1 0 
16 Usha A 22 2 Primi Primi 36 1 1 2 150 100 4.6 2 1 12 1 2.8 1 0 
17 Hema A 21 1 Primi Primi 30 2 2 1 120 90 4.2 2 1 15 1 1.5 1 0 
18 Janasamariamm A 21 2 MULTI G2P1L1 38 2 1 2 190 110 5 2 1 12 1 2 1 0 
19 Muniammal A 21 2 MULTI G2P1L1 32 2 1 2 180 110 4.6 1 1 15 1 2 1 0 
20 Petchi A 32 2 MULTI G2P1L1 28 2 5 2 150 100 4.8 2 1 12 1 1.9 1 0 
21 Kalaiselvi A 25 2 Primi Primi 30 2 4 2 160 110 5.2 2 1 11 1 2.4 1 0 
22 Meenachi A 22 2 MULTI G2P1L1 38 1 1 1 140 100 4.4 2 2 8 1 2.8 1 0 
S.No. Name Group Age yrs 
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Unbook
ed 
parity Obst. Code 
GA
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of 
cons.
At 
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No. of 
fits 
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adm. 
HT BP SYS DIA 
Sr. 
Mg.
mg/
dl 
MOI MOD
Admn. 
Deliver 
interval
hrs 
Condition 
after del 
mother 
B. 
Weight
kg 
Baby
No.of 
fits 
after 
deli. 
23 Sabrisa Banu A 28 2 Primi Primi 30 2 4 2 160 110 4.8 2 1 10 1 1.1 3 0
24 Muthammal A 20 2 Primi Primi 34 2 2 2 180 110 5 2 1 11 1 2 1 1 
25 Chitra A 28 1 Primi Primi 32 1 3 2 160 100 5.2 2 1 10 1 1.9 3 0 
26 Rajalakshmi A 24 1 Primi Primi 36 2 1 1 130 80 4.6 2 1 18 1 2 3 0 
27 Pitchaiammal A 21 2 Primi Primi 30 2 2 2 150 90 4.8 2 1 10 1 1.6 1 0 
28 Murugeswari A 20 1 Primi Primi 38 2 3 2 160 110 4.6 2 1 12 1 2.6 3 0 
29 Muthulaxmi A 18 2 Primi Primi 22 2 12 2 200 100 4.4 2 1 6 1 0.9 - 1 
30 Latha A 22 2 Primi Primi 32 1 2 2 160 100 4.8 2 1 14 1 1.8 1 0 
31 Murugasali B 22 1 Primi Primi 38 2 1 2 200 160 4.6 3 1 18 1 2.2 1 0 
32 Selvi B 24 1 Primi Primi 22 1 2 2 150 110 4.8 2 1 9 1 0.9 2 0 
33 Chitra B 24 2 MULTI G2P1L1 30 2 6 2 160 120 5.2 2 1 6 1 0.8 2 0 
34 Thanalaxmi B 22 2 Primi Primi 38 2 2 2 190 150 4.8 1 1 10 1 2.6 1 1 
35 Shanthi B 20 1 Primi Primi 24 2 1 1 130 100 5.2 2 1 16 1 1.7 3 0 
36 Gurupriya B 22 2 Primi Primi 30 1 4 1 130 90 5 2 1 6 1 1.5 2 0 
37 Meena  B 24 2 MULTI G2P1L1 30 1 2 2 150 100 5.4 1 1 8 1 2 1 0 
38 Nagalaxmi B 18 2 MULTI G2P1L1 34 2 3 2 160 110 5.2 1 1 8 1 1.8 1 1
39 Murugeswari B 20 1 MULTI G3A2 28 2 4 2 170 110 4.6 1 1 12 1 3.2 3 0 
40 Karthigai Rani B 24 1 MULTI G2P1L1 38 2 1 2 200 150 4.8 2 1 12 1 1.6 1 0 
41 Lakshmi B 24 1 MULTI G2P2L2 30 1 1 2 170 110 4.4 2 1 22 1 1.6 3 0 
42 Rajeswari B 20 2 Primi Primi 28 2 2 1 140 100 4.8 2 1 16 1 1.1 1 0 
43 Arulmozhi B 23 1 Primi Primi 36 2 2 2 160 110 4.4 2 2 6 1 2 1 0 
44 Punithavathi B 20 1 Primi Primi 30 2 2 2 160 120 5.8 2 1 18 1 1.75 1 0 
45 Muniammal B 25 2 Primi Primi 34 2 3 2 170 110 4.8 2 1 22 1 1.6 3 0 
46 Shanthi B 26 2 MULTI G3P2L2 38 1 1 2 150 100 4.6 1 2 6 1 2.8 1 0 
S.No. Name Group Age yrs 
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Unbook
ed 
parity Obst. Code 
GA
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of 
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HT BP SYS DIA 
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dl 
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47 Selvapathi B 30 2 MULTI G3P1L1A1 34 1 2 2 150 100 5.2 2 1 10 1 2.5 1 0
48 Chironammal B 18 1 Primi Primi 34 2 4 2 170 130 4.8 2 1 6 1 1.8 1 0 
49 Gandhi mathi B 25 2 MULTI G2P1L1 28 2 2 2 160 120 5.4 2 1 12 1 1.2 2 1 
50 Alagurani B 19 2 Primi Primi 38 1 3 2 150 110 5.8 2 1 14 1 2 1 0 
51 Radhalaxmi B 25 2 MULTI G4P2L1A1 32 2 2 1 110 70 4.8 2 1 18 1 1.5 1 0 
52 
Sundara 
pandiammal B 20 1 Primi Primi 34 1 1 2 150 110 5.6 2 1 7 1 1.9 1 0 
53 Ramjan B 20 2 Primi Primi 20 2 2 2 160 120 5 - 1 0.3 1 2.1 1 0
54 Chandra B 25 2 MULTI G3P2L2 34 2 3 2 150 110 5.2 2 1 6 1 2.2 1 0 
55 Manickam B 22 2 Primi Primi 26 1 5 2 170 120 5.4 2 1 14 1 1.2 3 0 
56 Rajeswari B 23 2 Primi Primi 32 2 1 2 180 100 4.6 2 1 12 1 2.5 3 0 
57 Muthurakku B 19 2 Primi Primi 30 1 1 1 140 100 5.6 2 1 15 1 1.5 1 0 
58 Shanthi B 35 2 Primi Primi 24 1 2 1 140 110 4.8 2 1 16 1 900gms 2 1 
59 Vijayalakshmi B 25 2 MULTI G2P1L1 28 2 5 2 180 120 5.2 2 1 18 1 1.5 1 1 
60 Pitchaiammal B 21 1 Primi Primi 32 2 2 2 150 110 4.6 2 1 11 1 2.25 1 - 
 
ABBREVIATIONS 
 
GA  - Gestational Age      Sr. Mg - Serum Magnesium 
 
BP Sys - Systolic blood pressure     DIA  - Diastolic blood pressure 
 
Group          Level of Consciousness 
Group A - Dhaka Regimen      1  - Conscious 
Group B - Pritchard Regimen      2  - Semi conscious 
 
Booking Status         MOI  - Mode of Induction 
1  - Booked       1  - Syntocinon  
2  - Unbooked       2  - Prostaglandin E2 gel  
             
MOD  - Mode of Delivery      Condition of mother after delivery 
1  - Vaginal delivery      1  - Alive 
2  - LSCS        2  - Dead 
 
Condition of mother after delivery 
1  - Alive 
2  - Still born 
3  - Neonatal death 
 
